{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:13:22Z","timestamp":1790957602000,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}],"id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s13318-019-00590-8","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T11:03:08Z","timestamp":1574766188000},"page":"227-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Effect of Multiple-Dose Aprocitentan Administration on the Pharmacokinetics of Midazolam in Healthy Male Subjects"],"prefix":"10.1007","volume":"45","author":[{"given":"Patricia N.","family":"Sidharta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Dingemanse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"issue":"3","key":"590_CR1","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1124\/jpet.118.253864","volume":"368","author":"F Trensz","year":"2019","unstructured":"Trensz F, Bortolamiol C, Kramberg M, Wanner D, Hadana H, Rey M, Strasser DS, Delahaye S, Hess P, Vezzali E, Mentzel U, Menard J, Clozel M, Iglarz M. Pharmacological characterization of aprocitentan, a dual endothelin receptor antagonist, alone and in combination with blockers of the renin angiotensin system, in two models of experimental hypertension. J Pharmacol Exp Ther. 2019;368(3):462\u201373.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"590_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41569-019-0176-3","volume":"16","author":"N Dhaun","year":"2019","unstructured":"Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. Nat Rev Cardiol. 2019;16(8):491\u2013502.","journal-title":"Nat Rev Cardiol"},{"issue":"8926","key":"590_CR3","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S0140-6736(94)92827-4","volume":"344","author":"WG Haynes","year":"1994","unstructured":"Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344(8926):852\u20134.","journal-title":"Lancet"},{"issue":"6163","key":"590_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/332411a0","volume":"332","author":"M Yanagisawa","year":"1988","unstructured":"Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411\u20135.","journal-title":"Nature"},{"issue":"7","key":"590_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11892-019-1161-2","volume":"19","author":"R Jagannathan","year":"2019","unstructured":"Jagannathan R, Patel SA, Ali MK, Narayan KMV. Global updates on cardiovascular disease mortality trends and attribution of traditional risk factors. Curr Diab Rep. 2019;19(7):44.","journal-title":"Curr Diab Rep"},{"issue":"6","key":"590_CR6","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269\u2013324.","journal-title":"Hypertension"},{"issue":"33","key":"590_CR7","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, Group ESCSD. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104.","journal-title":"Eur Heart J"},{"key":"590_CR8","unstructured":"FDA (2018) U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: hypertension: conducting studies of drugs to treat patients on a background of multiple antihypertensive drugs. Silver Spring, MD, USA. Draft Guidance, July, 2018."},{"issue":"2","key":"590_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1161\/01.CIR.103.2.263","volume":"103","author":"F Elijovich","year":"2001","unstructured":"Elijovich F, Laffer CL, Amador E, Gavras H, Bresnahan MR, Schiffrin EL. Regulation of plasma endothelin by salt in salt-sensitive hypertension. Circulation. 2001;103(2):263\u20138.","journal-title":"Circulation"},{"key":"590_CR10","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2147\/DDDT.S199051","volume":"13","author":"PN Sidharta","year":"2019","unstructured":"Sidharta PN, Melchior M, Kankam MK, Dingemanse J. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects. Drug Des Devel Ther. 2019;13:949\u201364.","journal-title":"Drug Des Devel Ther"},{"issue":"S1","key":"590_CR11","first-page":"14","volume":"8","author":"PN Sidharta","year":"2019","unstructured":"Sidharta PN, Fischer H, Delahaye S, Dingemanse J. Absorption, distribution, metabolism and excretion of aprocitentan, a dual endothelin receptor antagonist, in humans (Abstract). Clin Pharmacol Drug Dev. 2019;8(S1):14\u20135.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"590_CR12","unstructured":"EMA (2012) European Medicines Agency (EMA) \u2013 Committee for Medicinal Products for Human use (CHMP): Guideline on the investigation of drug interactions. (CPMP\/EWP\/560\/95\/Rev.1 Corr. 2). London, UK. 21 June 2012."},{"key":"590_CR13","unstructured":"FDA (2017) U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Guidance for industry: clinical drug interaction studies- study design, data analysis, and clinical implications. Silver Spring, MD."},{"issue":"1","key":"590_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF00547375","volume":"29","author":"LD Bornemann","year":"1985","unstructured":"Bornemann LD, Min BH, Crews T, Rees MM, Blumenthal HP, Colburn WA, Patel IH. Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharmacol. 1985;29(1):91\u20135.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"590_CR15","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00228-017-2282-7","volume":"73","author":"PE Juif","year":"2017","unstructured":"Juif PE, Boehler M, Donazzolo Y, Bruderer S, Dingemanse J. A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects. Eur J Clin Pharmacol. 2017;73(9):1121\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"590_CR16","unstructured":"FDA (2017) U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for Industry. Silver Spring, MD: December 2017."},{"key":"590_CR17","unstructured":"EMA (2010) European Medicines Agency (EMA) \u2013 Committee for Medicinal Products for Human use (CHMP): Guideline on the investigation of bioequivalence. (CPMP\/EWP\/QWP\/1401\/98 Rev.1 Corr). London, UK. 01 August 2010."},{"issue":"1","key":"590_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103\u201341.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"590_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/clpt.1994.60","volume":"55","author":"KT Olkkola","year":"1994","unstructured":"Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994;55(5):481\u20135.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"590_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0009-9236(98)90146-1","volume":"64","author":"JC Gorski","year":"1998","unstructured":"Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O\u2019Mara EM Jr, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 1998;64(2):133\u201343.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"590_CR21","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1124\/dmd.113.052316","volume":"41","author":"L Bjorkhem-Bergman","year":"2013","unstructured":"Bjorkhem-Bergman L, Backstrom T, Nylen H, Ronquist-Nii Y, Bredberg E, Andersson TB, Bertilsson L, Diczfalusy U. Comparison of endogenous 4beta-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. Drug Metab Dispos. 2013;41(8):1488\u201393.","journal-title":"Drug Metab Dispos"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-019-00590-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-019-00590-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-019-00590-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T01:27:39Z","timestamp":1606267659000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-019-00590-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["590"],"URL":"https:\/\/doi.org\/10.1007\/s13318-019-00590-8","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,26]]},"assertion":[{"value":"26 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Actelion Pharmaceuticals Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PNS and JD are current employees of Idorsia Pharmaceuticals Ltd and former employees of Actelion Pharmaceuticals Ltd, the company that funded the study. The authors report no other conflict of interest in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study (NCT02841761) followed the principles of the Declaration of Helsinki, its amendments, and good clinical practice, and the protocol was approved by an Independent Review Board (Integreview IRB, Austin, TX, USA).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All subjects provided written informed consent prior to screening.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}